Tissue plasminogen activator, plasminogen activator inhibitors, and activator-inhibitor complex in liver disease

K Leiper, A Croll, N A Booth, N R Moore, T Sinclair, B Bennett

Abstract

Aims—To identify the relative contribution of plasminogen activators, particularly tissue plasminogen activator (t-PA) and specific plasminogen activator inhibitors (PAI-1, PAI-2), to the fibrinolytic changes associated with various types of liver disease or severe chemical and physical damage to the liver.

Methods—Platelet rich (PRP) and platelet poor plasma (PPP) from patients with alcoholic cirrhosis, primary biliary cirrhosis, hepatic malignancy, or paracetamol overdose, or who were undergoing partial hepatectomy or liver transplantation, were assayed for t-PA, PAI-1, t-PA-PAI-1 complex and PAI-2 antigen values using specific enzyme linked immunosorbent assays (ELISAs) developed in this laboratory.

Results—Appreciable increases in the plasma concentration of t-PA, PAI-1, and t-PA-PAI-1 were seen in patients with alcoholic cirrhosis, primary biliary cirrhosis, and hepatic malignancy. Liver damage due to paracetamol overdose and partial hepatectomy both resulted in a striking increase in plasma PAI-1 concentration, although concentrations of t-PA and t-PA-PAI-1 complex were less affected. Concentrations of t-PA, PAI-1, and t-PA-PAI-1 complex returned to near normal values after successful liver transplantation in a patient with chronic active hepatitis. PAI-2 was also detected in several patients with chronic liver disorders.

Conclusions—Haemorrhage due to fibrinolytic bleeding is commonly associated with liver disease. The patients studied here all had appreciable increases in circulating t-PA antigen concentrations. This was associated with increased concentrations of PAI-1 antigen and t-PA-PAI-1 complex and the balance between activator and inhibitor did not result in systemic plasmin generation. Reduced PAI-1 activity in cirrhosis or a critical difference in the ratio of t-PA to PAI-1 concentrations may explain the enhanced plasminogen activator activity previously noted in cirrhosis but not metastatic disease. Reduced hepatic clearance of t-PA and t-PA-PAI-1 complex due to impaired liver function may account for increased concentrations of free and complexed t-PA.

Liver disease is associated with several abnormalities of the fibrinolytic system. Early studies of "overall fibrinolytic activity" showed that it was increased in hepatic cirrhosis.1-4 This finding might be explained by increased plasmin activity secondary to the reduced concentrations of the principal plasmin inhibitor (α1 plasminogen inhibitor) observed in cirrhosis5; however, major generation of complexes of plasmin and α1 plasmin inhibitor was not observed in the plasma of patients with cirrhosis, despite the presence of large amounts of free plasminogen activator (PA) and low α1 antiplasmin concentrations.9 Enhanced overall fibrinolytic activity in plasma probably reflects principally increased circulation of plasminogen activator in cirrhosis and evidence shows raised t-PA and u-PA activity6 and t-PA antigen8 in such patients. Reduced hepatic clearance of PA may contribute to raised plasma activities of PA in patients with cirrhosis.7 Alternatively, reduced concentrations of inhibitors of PA might account for raised PA activity. However, concentrations of such inhibitors were normal or increased in previous studies on hepatic cirrhosis,8 a fact which might account for the failure to generate plasmin in the circulation indicated above.

In contrast with hepatic cirrhosis, patients with hepatic malignancy, primary or secondary, have usually depressed overall fibrinolytic activity.3,11 However, raised concentrations of PA and u-PA antigen have recently been reported.10 If these were associated with high PAI-1 values this might explain the finding of reduced fibrinolytic activity. Few data are available on forms of liver disease other than alcoholic cirrhosis and malignancy and no systematic search for both the principal inhibitors of PA, PAI-1, and PAI-2 has been made in liver disease. We studied t-PA, PAI-1, t-PA-PAI-1 complex, and PAI-2 in several forms of liver disease to clarify the behaviour of the fibrinolytic system when hepatic function is abnormal.

Methods

Twenty five patients with liver disorders were studied. Twelve were identified as having alcoholic cirrhosis and five as having primary biliary cirrhosis on the basis of appropriate clinical history, biochemical results, autoantibody values, and results of liver biopsy. Five patients had extensive hepatic metastatic disease identified on liver scanning, all having clearly defined primary sites and clinical and biochemical evidence of severe liver
dysfunction. Two patients were studied on admission to hospital immediately after severe paracetamol overdose as a model for acute chemical hepatic damage. A further patient was studied sequentially over the period of partial hepatectomy for a very extensive benign adenoma; this patient serves as a model for acute physical hepatic injury. One patient with end stage liver failure due to chronic active hepatitis was studied several weeks and several weeks after liver transplantation.

Blood samples were taken into 0·1 volume of 0.13 M sodium citrate between 8·30 and 9·30 am with minimal stasis and trauma. Plasma essentially free of platelets (PFP) was prepared by centrifugation at 4 °C for 30 minutes at 1850 × g. Platelet rich plasma (PRP) was obtained by centrifugation at 170 × g for 10 minutes at room temperature. The platelets were then lysed by use of an MSE ultrasonic disintegrator at five second bursts at full power. Platelets were counted using a Coulter Thrombocounter C for PFP and PRP both before and after sonication. Thereafter all samples were stored in small aliquots at −70 °C, thawing of samples being kept to a minimum.

Liver function tests were performed by standard techniques. PAI-1, t-PA, t-PA-PAI-1 complex, and PAI-2 were measured by specific enzyme linked immunosorbent assays (ELISAs) as described previously.13-15

The Wilcoxon signed rank test for unpaired data was used to compare results; p values are quoted for comparisons between patients and normal controls.

Results
Table 1 summarises platelet counts and the results of clinical biochemistry for the groups of patients with different forms of liver disease. In the three main groups of liver disorder studied—namely alcoholic cirrhosis, primary biliary cirrhosis, and hepatic malignancy—plasma concentrations of t-PA, PAI-1, and t-PA-PAI-1 complex antigens were appreciably raised (table 2). t-PA and t-PA-PAI-1 complex antigen concentrations were highest in alcoholic cirrhosis, while PAI-1 antigen concentrations was highest in hepatic metastases. The concentration of PAI-1 in the platelet pool in each group was reduced; however, this reflected reduced platelet counts and the mean platelet content of PAI-1 did not differ from that of normal subjects (data not shown).

The two patients with severe chemical damage to the liver caused by paracetamol overdose showed strikingly raised concentrations of PAI-1 but only a modest increase in t-PA and t-PA-PAI-1 antigen (table 2).

The changes in PAI-1, t-PA, and t-PA-PAI-1 complex antigen induced by acute mechanical trauma to the liver (partial hepatectomy) were also studied (figure). A dramatic rise and rapid fall in PAI-1 antigen values was observed over 48 hours. Concentrations of t-PA and t-PA-PAI-1 complex rose also, but these rises followed rather than coincided with the PAI-1 response.

In the patient with end stage liver failure, concentrations of t-PA, PAI-1, and t-PA-PAI-1 complex before transplantation were all

Changes in plasma concentrations of t-PA (●), PAI-1 (□), and t-PA-PAI-1 complex (▲) after partial hepatectomy.

Table 1 Mean values of biochemical variables of liver function in patients with different forms of liver disease

<table>
<thead>
<tr>
<th></th>
<th>Albumin (g/l)</th>
<th>Bilirubin (μmoll)</th>
<th>Alanine phosphatase (U/l)</th>
<th>Amino aspartase transaminase (U/l)</th>
<th>γ Glutamyl transferase (U/l)</th>
<th>Plasdlet count (10⁶)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcoholic cirrhosis</td>
<td>32</td>
<td>105</td>
<td>178</td>
<td>83</td>
<td>181</td>
<td>200</td>
</tr>
<tr>
<td>Primary biliary cirrhosis</td>
<td>37</td>
<td>67</td>
<td>423</td>
<td>100</td>
<td>690</td>
<td>122</td>
</tr>
<tr>
<td>Hepatic metastases</td>
<td>39</td>
<td>94</td>
<td>894</td>
<td>158</td>
<td>380</td>
<td>188</td>
</tr>
<tr>
<td>Paracetamol overdose</td>
<td>40</td>
<td>15</td>
<td>30</td>
<td>38</td>
<td>10</td>
<td>200</td>
</tr>
<tr>
<td>Normal values</td>
<td>37-49</td>
<td>&lt;22</td>
<td>&lt;105</td>
<td>&lt;31</td>
<td>&lt;35</td>
<td>150-400</td>
</tr>
</tbody>
</table>

Table 2 Mean (SD) concentrations of t-PA, PAI-1, PAI-2, and t-PA-PAI-1 complex in platelet free plasma of patients with different forms of liver disease

<table>
<thead>
<tr>
<th></th>
<th>t-PA (ng/ml)</th>
<th>PAI-1 (ng/ml)</th>
<th>t-PA-PAI-1 complex (pmol/l)</th>
<th>PAI-2 (ng/ml)</th>
<th>α2 Antiplasmin (% normal)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcoholic cirrhosis</td>
<td>47·1 (20-8)**</td>
<td>55·9 (35-5)**</td>
<td>804·7 (534-6)**</td>
<td>8·2 (6-8)</td>
<td>69·0 (18-7)**</td>
</tr>
<tr>
<td>Primary biliary cirrhosis</td>
<td>31·6 (9-0)**</td>
<td>57·6 (31-3)**</td>
<td>413·0 (134-2)**</td>
<td>8·4 (0-2)</td>
<td>72·2 (24-9)**</td>
</tr>
<tr>
<td>Hepatic metastases</td>
<td>32·3 (10-9)**</td>
<td>72·7 (65-7)**</td>
<td>372·8 (279-6)**</td>
<td>9·5 (0-2)</td>
<td>91·0 (21-0)*</td>
</tr>
<tr>
<td>Paracetamol overdose</td>
<td>20·36**</td>
<td>200·8**</td>
<td>0</td>
<td>16·5</td>
<td>NA</td>
</tr>
<tr>
<td>Normal values</td>
<td>5·1 (2-0)</td>
<td>21·0 (7-2)</td>
<td>60·3 (45-5)</td>
<td>0</td>
<td>112·3 (11-2)</td>
</tr>
</tbody>
</table>

NA = not assayed.

*p < 0·01, **p < 0·001.
Table 3 Concentrations of t-PA, PAI-1, and t-PA–PAI-1 complex in platelet-free plasma before and after liver transplantation

<table>
<thead>
<tr>
<th></th>
<th>t-PA (ng/ml)</th>
<th>PAI-1 (ng/ml)</th>
<th>t-PA–PAI-1 complex (pmol/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Before</td>
<td>81-2</td>
<td>97-7</td>
<td>659-3</td>
</tr>
<tr>
<td>After</td>
<td>16-9</td>
<td>12-9</td>
<td>31-3</td>
</tr>
</tbody>
</table>

strikingly raised; all returned to near normal after successful transplantation (table 3).

Ten of the 12 patients with alcoholic cirrhosis, two of the five with primary biliary cirrhosis, two of the four with hepatic malignancies and one of the two with paracetamol overdose had detectable plasma concentrations of PAI-2 (table 2).

Reduced circulating concentrations of α2 antiplasmin were found in patients with alcoholic cirrhosis and primary biliary cirrhosis, with a less pronounced reduction in patients with hepatic metastases (table 2).

Discussion

These observations extend the findings of previous studies on proteolytic disorders in liver disease. Earlier studies have shown enhanced overall fibrinolytic activity in hepatic cirrhosis with no increase, or more commonly, a decrease in overall fibrinolytic activity in patients with hepatic metastases. These early studies used techniques such as the euglobulin lysis time reflecting primarily plasminogen activator concentration, and t-PA antigen has been shown to be raised in cirrhosis.10,11 Our earlier studies have shown that despite raised concentrations of PA and reduced concentration of α2 antiplasmin there was no evidence of significant generation of plasmin-α2 antiplasmin complexes in patients with cirrhosis.6,8 This suggested that in cirrhosis there was sufficient inhibitor of PA present in plasma to prevent large scale generation of plasmin by the increased amounts of PA present. This study confirms this suggestion, as there is clearly a considerably increased concentration of PAI-1 in the plasma of cirrhotic patients, with generation of large quantities of t-PA–PAI-1 complex.

In the three major liver diseases studied—alcoholic cirrhosis, primary biliary cirrhosis, and metastatic liver disease—concentrations of t-PA, PAI-1 antigen, and t-PA–PAI-1 complexes were all considerably raised. Despite the raised concentration of PAI-1 antigen noted here, we observed reduced PA-I activity in hepatic cirrhosis12,18 and others have reported similar findings13; this may reflect large scale generation of t-PA–PAI-1 complex in cirrhosis and explain why significant t-PA activity remains, accounting for enhanced overall fibrinolytic activity. The differences in overall fibrinolytic activity between patients with cirrhosis and those with metastatic liver disease may depend on a critical balance between t-PA and PAI-1. Concentrations of t-PA and PAI-1 were raised in all patient groups, but clearly the ratio of t-PA to PAI-1 antigen concentrations was higher in cirrhosis than in metastatic disease (table 2).

The highest concentrations of PAI-1 antigen were noted in patients with chemical (paracetamol) or physical (partial hepatectomy) injury to the liver. Paracetamol overdose represents a particularly acute form of liver damage and PAI-1 concentrations clearly were raised early, before large changes in standard biochemical variables of liver damage were detected; in this it is similar to the well-known prolongation of the prothrombin time after overdose. Similar very early release of PAI-1 antigen occurred during partial hepatectomy in the one patient studied and this occurred before any change in concentration of t-PA or t-PA–PAI-1 complex. These observations suggest that in liver disease the source of raised plasma concentrations of PAI-1 is the liver itself, PAI-1 being released from damaged liver cells at least in some situations. The source of raised concentrations of t-PA is less clear. The liver is not rich in t-PA but is responsible for clearance of t-PA from the circulation both in its free and complexed forms.19-21 In liver disease it seems probable that raised concentrations of t-PA and t-PA–PAI-1 complexes result in part at least from reduced clearance mechanisms of both types. The restoration to virtual normality of t-PA, PAI-1, and t-PA–PAI-1 complexes after liver transplantation strikingly emphasises the central role of the liver in securing homeostasis in the fibrinolytic system.

PAI-2 is usually detected in pregnancy and has not been reported before in liver disease. This inhibitor is, however, synthesised by several cell lines in culture, including monocytes, macrophages, and certain tumour cells. In this study small but significant quantities of PAI-2 were detected by ELISA and by the independent technique of non-denaturing gel electrophoresis with zymography rendered specific by antibody quenching.22 The presence of PAI-2 may represent a response to the u-PA we have shown in the plasma in some forms of liver disease2 and which is often present in malignant cells.23 Alternatively, depressed hepatic function may reduce clearance mechanisms for PAI-2, which are as yet undefined, and may result in small quantities of PAI-2 produced by monocytes, etc., accumulating in the plasma.

In summary, this study shows that patients with major liver disease tend to have high concentrations of t-PA, PAI-1, and t-PA–PAI-1 complex as detected by immunonassay, regardless of the type of liver disease. High concentrations of PAI-1 and perhaps PAI-2 may be an important factor in preventing generation of plasmin in these patients but do not account for the difference in overall fibrinolytic activity between patients with different forms of liver disease. Altered functional activity of the inhibitors or critical alterations of the ratio of t-PA to PAI-1 concentration may be factors in the differences observed in PA activity. The raised concentrations of PAI-1 may reflect in some cases release of PAI-1 from damaged liver cells, but increased PAI-1...
Tissue plasminogen activator-inhibitor complex in liver disease

synthesis within or outwith the liver as a result of the metabolic disruption occurring in liver disease may occur. Raised t-PA concentrations may reflect, in part, reduced clearance by the damaged liver.

3 Fletcher AP, Biederman O, Moore D, Aikaesig N, Sherry S. Abnormal plasminogen-plasmin system activity (fibri
21 Wing LR, Bennett B, Booth NA. The receptor for tissue plasminogen activator (t-PA) in complex with its inhibitor, PAI-1, on human hepatocytes. FEBS 1991; 278:95–7.
Tissue plasminogen activator, plasminogen activator inhibitors, and activator-inhibitor complex in liver disease.
K Leiper, A Croll, N A Booth, N R Moore, T Sinclair and B Bennett

doi: 10.1136/jcp.47.3.214

Updated information and services can be found at:
http://jcp.bmj.com/content/47/3/214

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/